Parameter
| Biomarker | CD82, CD55, and CD36 | Full name | Cluster of differentiation 82, 55 and 36 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Blood (single-cell RNA sequencing, CyTOF) | ||
| Pathobiological Mechanisms | Significantly overexpressed without being influenced by COO and C-MYC | ||||
| Clinical Availability Status | Research validation phase: Screening and validation of 18 patients, requiring large-sample assessment and simplified testing methods. | ||||
| Notes and Dynamics | Develop standard flow cytometry panels to reduce costs and improve accessibility. | ||||